Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:IRMD NASDAQ:RXST NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.96+4.6%$3.01$1.60▼$16.55$293.57M1.181.08 million shs567,348 shsIRMDiRadimed$59.85+0.0%$56.82$42.34▼$63.29$761.23M0.9144,240 shs24,015 shsRXSTRxSight$8.31+4.5%$14.26$6.32▼$58.23$338.45M1.21797,932 shs2.99 million shsSIBNSiBone$18.81+2.0%$18.07$11.70▼$20.05$801.38M0.93392,120 shs85,082 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics+7.08%+11.50%+17.03%+103.23%-64.37%IRMDiRadimed+0.83%-2.81%-1.63%+19.38%+36.96%RXSTRxSight-37.84%-39.50%-48.04%-43.97%-86.05%SIBNSiBone+1.49%+0.05%-2.23%+39.17%+37.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics1.0905 of 5 stars3.61.00.00.00.00.80.0IRMDiRadimed4.6036 of 5 stars2.52.02.54.42.03.31.9RXSTRxSight2.3504 of 5 stars4.01.00.00.01.51.70.6SIBNSiBone4.0332 of 5 stars2.55.00.03.32.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56217.46% UpsideIRMDiRadimed 3.00Buy$72.0020.31% UpsideRXSTRxSight 1.90Reduce$23.90187.61% UpsideSIBNSiBone 3.00Buy$22.5019.65% UpsideCurrent Analyst Ratings BreakdownLatest CATX, IRMD, SIBN, and RXST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RXSTRxSightJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $9.007/9/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.007/9/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.007/9/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $9.007/9/2025RXSTRxSightOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/9/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.007/9/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.007/9/2025RXSTRxSightBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AIRMDiRadimed$73.24M10.39$1.60 per share37.49$6.85 per share8.74RXSTRxSight$139.93M2.41N/AN/A$6.98 per share1.19SIBNSiBone$176.60M4.54N/AN/A$3.98 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)IRMDiRadimed$19.23M$1.5538.6129.92N/A26.33%23.28%20.59%7/30/2025 (Estimated)RXSTRxSight-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/7/2025 (Estimated)SIBNSiBone-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)Latest CATX, IRMD, SIBN, and RXST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IRMDiRadimed$0.45N/AN/AN/AN/AN/A8/7/2025Q2 2025RXSTRxSight-$0.0363N/AN/AN/A$39.78 millionN/A8/4/2025Q2 2025SIBNSiBone-$0.19N/AN/AN/A$48.12 millionN/A5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million5/5/2025Q1 2025SIBNSiBone-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AIRMDiRadimed$0.681.14%N/A43.87%1 YearsRXSTRxSightN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ALatest CATX, IRMD, SIBN, and RXST DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60IRMDiRadimedN/A8.877.62RXSTRxSightN/A12.6811.65SIBNSiBone0.218.537.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%IRMDiRadimed92.34%RXSTRxSight78.78%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%IRMDiRadimed36.80%RXSTRxSight9.57%SIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableRXSTRxSight22040.64 million36.75 millionOptionableSIBNSiBone35042.62 million40.91 millionOptionableCATX, IRMD, SIBN, and RXST HeadlinesRecent News About These CompaniesSiBone (NASDAQ:SIBN) Shares Sold by Brown Advisory Inc.July 9 at 6:26 AM | marketbeat.comAnshul Maheshwari Sells 5,005 Shares of SiBone (NASDAQ:SIBN) StockJuly 9 at 4:41 AM | americanbankingnews.comMichael A. Pisetsky Sells 3,127 Shares of SiBone (NASDAQ:SIBN) StockJuly 9 at 4:41 AM | americanbankingnews.comInsider Selling: SiBone (NASDAQ:SIBN) CEO Sells 757 Shares of StockJuly 8 at 4:54 AM | insidertrades.comLaura Francis Sells 757 Shares of SiBone (NASDAQ:SIBN) StockJuly 7 at 9:29 PM | marketbeat.comSiBone (NASDAQ:SIBN) SVP Michael A. Pisetsky Sells 3,127 SharesJuly 7 at 9:29 PM | marketbeat.comSiBone (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 3,310 SharesJuly 7 at 9:29 PM | marketbeat.comSiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 5,005 SharesJuly 7 at 9:29 PM | marketbeat.comAll You Need to Know About Si-Bone (SIBN) Rating Upgrade to BuyJuly 7 at 1:01 PM | zacks.comCalamos Advisors LLC Buys New Shares in SiBone (NASDAQ:SIBN)July 7 at 4:56 AM | marketbeat.comLisanti Capital Growth LLC Makes New Investment in SiBone (NASDAQ:SIBN)June 29, 2025 | marketbeat.comSI-BONE (NASDAQ:SIBN) Sees Unusually-High Trading Volume - Here's WhyJune 13, 2025 | marketbeat.comCantor Fitzgerald Weighs in on SI-BONE FY2026 EarningsJune 11, 2025 | marketbeat.comHarbor Capital Advisors Inc. Sells 308,333 Shares of SI-BONE, Inc. (NASDAQ:SIBN)June 10, 2025 | marketbeat.comSI-BONE to Truist Securities MedTech Conference on June 17, 2025June 4, 2025 | globenewswire.comSI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025May 28, 2025 | globenewswire.comSI-BONE’s SWOT analysis: stock poised for growth amid market expansionMay 27, 2025 | investing.comWall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?May 26, 2025 | zacks.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,424 Shares of StockMay 21, 2025 | insidertrades.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 4,937 Shares of StockMay 16, 2025 | insidertrades.com4 Recent Earnings Winners Riding Fresh Momentum in May (SIBN)...May 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCATX, IRMD, SIBN, and RXST Company DescriptionsPerspective Therapeutics NYSE:CATX$3.96 +0.18 (+4.63%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.iRadimed NASDAQ:IRMD$59.84 +0.03 (+0.04%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.RxSight NASDAQ:RXST$8.30 +0.35 (+4.42%) As of 02:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SiBone NASDAQ:SIBN$18.80 +0.37 (+1.98%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
